Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.

Abstract	The aim of this study is to clarify the relationship between serum 3-O-methyldopa (3-OMD) and the clinical effects of entacapone. The 3-OMD and maximum serum concentration (Cmax) of levodopa were measured in 21 Parkinson's Disease patients who took 100 mg levodopa / dopa decarboxylase inhibitor. After the administration of entacapone, the 3-OMD concentration and percentage of "on" time during waking hours (% of "on" time) were studied for 8 weeks. The 3-OMD concentration was reduced by 34%, and the increase in % of "on" time was 28% at the 8th week compared with baseline. We defined the COMT-index as [baseline 3-OMD concentration] / [levodopa Cmax when 100 mg levodopa was administered alone]. The COMT-index was significantly correlated with the increase in % of "on" time at the 8th week. In conclusion, the measurement of baseline 3-OMD and levodopa pharmacokinetics is useful for predicting the clinical effects of entacapone.
Authors	Aiko Ishihara, Takafumi Miyachi, Takeshi Nakamura, Toshiho Ohtsuki, Yasuhiro Kimura, Kenji Kihira, Takemori Yamawaki, Masayasu Matsumoto
Journal	Hiroshima journal of medical sciences (Hiroshima J Med Sci) Vol. 60 Issue 3 Pg. 57-62 (Sep 2011) ISSN: 0018-2052 [Print] Japan
PMID	22053701 (Publication Type: Journal Article)
Chemical References	Antiparkinson Agents Aromatic Amino Acid Decarboxylase Inhibitors Biomarkers Catechol O-Methyltransferase Inhibitors Catechols Enzyme Inhibitors Nitriles Tyrosine Levodopa entacapone Benserazide Catechol O-Methyltransferase Dopa Decarboxylase Carbidopa 3-methoxytyrosine
Topics	Aged Aged, 80 and over Antiparkinson Agents (pharmacokinetics, therapeutic use) Aromatic Amino Acid Decarboxylase Inhibitors Benserazide (therapeutic use) Biomarkers (blood) Carbidopa (therapeutic use) Catechol O-Methyltransferase (metabolism) Catechol O-Methyltransferase Inhibitors Catechols (therapeutic use) Disease Progression Dopa Decarboxylase (metabolism) Drug Therapy, Combination Enzyme Inhibitors (therapeutic use) Female Humans Japan Levodopa (pharmacokinetics, therapeutic use) Male Middle Aged Motor Activity (drug effects) Nitriles (therapeutic use) Parkinson Disease (blood, diagnosis, drug therapy, psychology) Prospective Studies Treatment Outcome Tyrosine (analogs & derivatives, blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!